Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Sampol, Antonia  [Clear All Filters]
2014
Vallejo C, Batlle M, Vázquez L, Solano C, Sampol A, Duarte R, Hernandez D, Lopez J, Rovira M, Jimenez S, et al. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica. 2014.
2020
Hernández-Boluda J-C, Pereira A, Alvarez-Larran A, Martín A-A, Benzaquen A, Aguirre L, Mora E, González P, Mora J, Dorado N, et al. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis. Biol Blood Marrow Transplant. 2020.
2021
Bataller A, Garrido A, Guijarro F, Oñate G, Díaz-Beyá M, Arnan M, Tormo M, Vives S, DE Llano MPaz Queipo, Coll R, et al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2021.
2022
Bailén R, Pascual-Cascón MJesús, Guerreiro M, López-Corral L, Chinea A, Bermúdez A, Sampol A, Heras I, García-Torres E, Torres M, et al. Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC. Transplant Cell Ther. 2022.
2024
López-Andrade B, Cunill V, Andreu V, Bento L, Segura-Guerrero M, Moñino A, Iglesias J, Julià MRosa, Durán MAntonia, Ballester MCarmen, et al. Plasma from patients undergoing allogeneic hematopoietic stem cell transplantation promotes NETOSIS and correlates with inflammatory parameters and clinical severity. Front Immunol. 2024;15:1353106.